Johnson & Johnson Dirección

Dirección controles de criterios 2/4

El CEO de Johnson & Johnson's es Joaquin Duato , nombrado en Jan 2022, tiene una permanencia de 2.25 años. compensación anual total es $28.40M, compuesta por 5.6% salario y 94.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.015% de las acciones de la empresa, por valor de €50.42M. La antigüedad media del equipo directivo y de la junta directiva es de 4.4 años y 4.7 años, respectivamente.

Información clave

Joaquin Duato

Chief Executive Officer (CEO)

US$28.4m

Compensación total

Porcentaje del salario del CEO	5.6%
Permanencia del CEO	2.4yrs
Participación del CEO	0.02%
Permanencia media de la dirección	4.5yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joaquin Duato en comparación con los beneficios de Johnson & Johnson?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensación vs. Mercado: La compensación total de Joaquin($USD28.40M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.03M).

Compensación vs. Ingresos: La compensación de Joaquin ha aumentado más de un 20% en el último año.

CEO

Joaquin Duato (61 yo)

2.4yrs

Permanencia

US$28,397,240

Compensación

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Joaquin Duato	CEO & Chairman	2.4yrs	US$28.40m	0.015% $ 49.5m
Joseph Wolk	Executive VP & CFO	5.9yrs	US$13.91m	0.0029% $ 9.6m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.2yrs	US$7.50m	0.0047% $ 15.2m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.4yrs	US$11.00m	0.0064% $ 21.0m
John Reed	Executive Vice President of Innovative Medicine	1.2yrs	US$20.65m	0.00048% $ 1.6m
Robert Decker	Controller & Chief Accounting Officer	4.5yrs	sin datos	0.00082% $ 2.7m
James Swanson	Executive VP & Chief Information Officer	4.6yrs	sin datos	0.00061% $ 2.0m
Jessica Moore	Vice President of Investor Relations	2.6yrs	sin datos	sin datos
Dirk Brinckman	Chief Compliance Officer	no data	sin datos	sin datos
Elizabeth Forminard	Executive VP & Chief Legal Officer	1.7yrs	sin datos	0.00035% $ 1.1m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	sin datos	sin datos
William Hait	Executive VP	17.4yrs	sin datos	0.0016% $ 5.3m

4.5yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de JNJ se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Joaquin Duato	CEO & Chairman	2.4yrs	US$28.40m	0.015% $ 49.5m
D. Davis	Independent Director	10yrs	US$350.00k	0% $ 0
Anne Mulcahy	Independent Director	15.4yrs	US$410.00k	0.00034% $ 1.1m
Hubert Joly	Independent Director	4.5yrs	US$320.00k	0.00021% $ 686.8k
Marillyn Hewson	Lead Independent Director	5.2yrs	US$360.00k	0.00012% $ 392.5k
Paula Johnson	Independent Director	1.3yrs	US$352.97k	0.000010% $ 32.7k
Mark McClellan	Independent Director	10.7yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	9yrs	US$355.00k	0% $ 0
Darius Adamczyk	Independent Director	2.3yrs	US$340.00k	0.000040% $ 130.8k
Jennifer Doudna	Independent Director	6.2yrs	US$320.00k	0% $ 0
Mark Weinberger	Independent Director	4.5yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	3.5yrs	US$340.00k	0% $ 0

4.8yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de JNJ se considera experimentada (4.7 años de antigüedad promedio).

Johnson & Johnson Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insider recently sold €1.3m worth of stock

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Recent updates

New major risk - Revenue and earnings growth

Johnson & Johnson to Report Q3, 2024 Results on Oct 15, 2024

Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes

Johnson & Johnson Announces the First Phase 3 Results for Tremfa® (Guselkumab) in Adult Patients with Moderate to Severe Active Crohn's Disease Program

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. for $850 million.

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Updated Results from an Open-Label, Multicenter, Multi-Cohort Phase 1 Study of the Safety and Efficacy of TAR-210

First quarter 2024 earnings released: EPS: US$1.35 (vs US$0.19 loss in 1Q 2023)

First quarter dividend of US$1.24 announced

First quarter 2024 earnings released: EPS: US$2.20 (vs US$0.026 loss in 1Q 2023)

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Announces New Analysis of Data from the PionEER AF-PCI Clinical Trial Demonstrating XARELTO®? (rivaroxaban)

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson to Showcase its Latest Innovations to Combat Cardiovascular Disease at ACC.24

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Opsynvi as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Recommends Carvykti®? (Ciltacabtagene Autoleucel) for the Early Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Insider recently sold €1.3m worth of stock

Johnson & Johnson, Annual General Meeting, Apr 25, 2024

Johnson & Johnson to Report Q2, 2024 Results on Jul 17, 2024

Johnson & Johnson Announces the First Data from FRONTIER 2, the Long-Term Extension of the Phase 2b FONTIER 1 Clinical Trial Evaluating JNJ-2113

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Ambrx Biopharma Inc. (NasdaqGS:AMAM) from a group of shareholders.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad